Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden

Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden

Publication date: Aug 31, 2021

This is an observational cohort study with retrospective analysis of prospectively collected data. The study cohort is constituted of all patients with relapsing-remitting multiple sclerosis (RRMS) treated with autologous stem cell transplantation (AHSCT) in Sweden from 2004 when the first AHSCT was performed until 31 December 2019. The study aims to describe the effectiveness, safety and patient reported outcomes of AHSCT for MS through real world data. Treatment related mortality will be analyzed from start of mobilization until the end of the study. For other adverse events the data collection will end 3 months post-transplantation. A statistical subgroup comparison of efficacy and safety between the conditioning regimens BEAM-ATG and Cy-ATG will be included within the study.

Concepts Keywords
Bone MRI
December Transplantation
Drugs Organ transplantation
Hematopoietic Bone marrow
Swedish Lymphology
Surgical oncology
Hematology
Transplantation medicine
Stem cells
Clinical medicine
Branches of biology
Medical specialties
ATG

Semantics

Type Source Name
disease MESH death
disease MESH Diagnosis
drug DRUGBANK Tricyclazole
disease MESH relapsing-remitting multiple sclerosis
disease MESH Multiple Sclerosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *